Literature DB >> 16207602

Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning.

Guillermo J Ruiz-Argüelles1, David Gómez-Almaguer, Jorge Vela-Ojeda, Amelia Morales-Toquero, Jóse David Gómez-Rangel, Miriam A García-Ruiz-Esparza, Briceida López-Martínez, Olga G Cantú-Rodríguez, César H Gutiérrez-Aguirrec.   

Abstract

Of a group of 149 patients who underwent allogeneic stem cell transplantation using the "Mexican approach", a nonablative preparative regimen, 49 individuals developed bone marrow relapse, and 8 patients developed extramedullary relapse (EMR). All EMR cases presented in patients who received allografts for myeloid malignancies. In contrast, bone marrow relapses presented in patients with myeloid or lymphoid malignancies. EMR presented 60 to 1010 days after the allograft and appeared in 3 cases as subcutaneous nodules in different parts of the body, in the vertebrae in 3 cases, and in the kidney and the breast in 1 case each. One patient had both subcutaneous nodules and epididymis EMR. When EMR was noted, acute graft-versus-host disease (GVHD) had presented in 4 patients, and limited forms of chronic GVHD were present in 3 patients. All but 1 of the patients were full chimeras when the EMR ensued, and the EMR preceded an overt hematologic relapse in all but 1 of the patients. Patients who experienced an overt hematologic relapse died 20 to 180 days (median, 40 days) after the EMR. The only individual alive 240 days after relapse shows no evidence of a full-blown hematologic relapse. An EMR after allogeneic hematopoietic stem cell transplantation usually has a bad prognosis and presents mainly in individuals with high-risk malignancies.

Entities:  

Mesh:

Year:  2005        PMID: 16207602     DOI: 10.1532/IJH97.04195

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  26 in total

1.  Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.

Authors:  G J Ruiz-Argüelles; D Gómez-Almaguer; A Ruiz-Argüelles; O González-Llano; O G Cantú; J C Jaime-Pérez
Journal:  Am J Hematol       Date:  2001-04       Impact factor: 10.047

2.  Flow cytometry in the clinical laboratory. Principles, applications and problems.

Authors:  A Ruiz-Arguelles
Journal:  Ann Biol Clin (Paris)       Date:  1992       Impact factor: 0.459

3.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

4.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.

Authors:  John E Levine; Thomas Braun; Samuel L Penza; Patrick Beatty; Kenneth Cornetta; Rodrigo Martino; William R Drobyski; A John Barrett; David L Porter; Sergio Giralt; Jose Leis; Houston E Holmes; Matthew Johnson; Mary Horowitz; Robert H Collins
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

5.  Assessment of residual disease in acute leukemia by means of polymerase chain reaction.

Authors:  G J Ruiz-Argüelles; J Garcés-Eisele; V Reyes-Núñez; B Pérez-Romano; A Ruiz-Argüelles; F J Ramírez-Cisneros; B López-Martínez; J D López-Tapia; L Rivadeneyra-Espinoza
Journal:  Rev Invest Clin       Date:  2000 Mar-Apr       Impact factor: 1.451

6.  High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation.

Authors:  K H Lee; J H Lee; S Kim; J S Lee; S H Kim; W K Kim
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

Review 7.  Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review.

Authors:  Benjamin Djulbegovic; Jerome Seidenfeld; Claudia Bonnell; Ambuj Kumar
Journal:  Cancer Control       Date:  2003 Jan-Feb       Impact factor: 3.302

Review 8.  Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  George E Georges; Rainer Storb
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

9.  Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy.

Authors:  A Kessinger; J O Armitage; J D Landmark; D M Smith; D D Weisenburger
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

10.  Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course.

Authors:  K-H Lee; J-H Lee; S-J Choi; J-H Lee; S Kim; M Seol; Y-S Lee; W-K Kim; E-J Seo; C-J Park; H-S Chi; J-S Lee
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

View more
  3 in total

1.  Extramedullary relapse following reduced intensity allogeneic hematopoietic cell transplant for adult acute myelogenous leukemia.

Authors:  Neil Kogut; Ni-Chun Tsai; Sandra H Thomas; Joycelynne Palmer; Tanya Paris; Joyce Murata-Collins; Stephen J Forman
Journal:  Leuk Lymphoma       Date:  2012-09-12

2.  Radiological imaging characteristics of intramammary hematological malignancies: results from a german multicenter study.

Authors:  Susanne Wienbeck; Hans Jonas Meyer; Johannes Uhlig; Aimee Herzog; Sogand Nemat; Andrea Teifke; Walter Heindel; Fritz Schäfer; Sonja Kinner; Alexey Surov
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

3.  Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature.

Authors:  Shalin Kothari; Geoffrey Herzig; Stephen Slone; Roger Herzig
Journal:  Springerplus       Date:  2013-02-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.